Rashi Dhir, Saiyam Chaturvedi 
Dealstreet

DMD Advocates acts on ChrysCapital's $100 million investment in New Delhi Centre for Sight

ChrysCapital is set to invest up to $100 million in Centre for Sight.

Bar & Bench

The New Delhi Centre for Sight (CFS) is expected to receive an investment of upto $100 million from ChrysCapital.

The transaction will be done by way of a primary infusion in CFS and through secondary acquisition of the entire stake held by Mahindra Holdings Limited.

DMD Advocates advised CFS on this investment by drafting and negotiation of the transaction documents, as well as in conducting a vendor legal due diligence of CFS, its subsidiaries and the centres operated by CFS.

The transaction was led by Rashi Dhir (Senior Partner and Head of Corporate) along with Saiyam Chaturvedi (Partner), Kajal Tandon (Principal Associate), Divay Rastogi (Principal Associate), Priyanka Hazarika (Senior Associate), Arnav Mithal (Associate), and Srishti Pandey (Associate).

Aishwarya Gupta (Senior Associate), Aditi Kumari (Associate), Ela Bharti (Associate), Jasmine Brar (Associate), and Tarush Bhandari (Associate) assisted the transaction team in the vendor due diligence exercise.

Centre for Sight

Founded in 1996 by Prof. Dr. Mahipal S. Sachdev, Centre for Sight has over 350 experienced doctors and a network of 85+ centers across the country.

The Centre for Sight Eye Institute in Dwarka, Delhi, is North India's largest private super-specialty eye hospital. Registered under the Nursing Home Act in multiple states and accredited by NABH.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

CCI imposes ₹ 213.14 crore penalty on Meta for abuse of dominant position

Byju's lenders accuse former management of attempting to dilute shareholding in Aakash Institute

Bombay High Court declines urgent hearing in PIL against Rashmi Shukla’s appointment as DGP, tenure extension

Roche vs Zydus: Supreme Court asks Delhi High Court to expeditiously decide cancer drug case

Bombay High Court upholds ECI's mobile phone ban in polling booths

SCROLL FOR NEXT